Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01868516 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
A Phase 2 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,635
- Enrollment target
NCT01868516: Completed Phase 2 study, sponsored by Targacept.
NCT01868516 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 1,635 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1129% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01868516, a Phase 2 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,635 participants
- Enrollment target
Study Summary
Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.
Primary Outcome
Micturition: Any voiding episode recorded by the patient as "urinated" either with or without incontinence.
Interventions
- DRUG Placebo
- DRUG dexmecamylamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,635 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT01868516 record still lists
NCT01868516 is an interventional study that assigns participants to a tested intervention. Its 1,635 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1129% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01868516 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01868516 about?
NCT01868516 is a clinical study titled "Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder". Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.
What is the current status of trial NCT01868516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,635 participants. The study started on 2013-05. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01868516?
The interventions under investigation include: Placebo (DRUG), dexmecamylamine (DRUG).
Who is sponsoring clinical trial NCT01868516?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01868516's enrollment target sits among peer trials
1,635 11th of 2000 higher than 1,990 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia